Loading…
Based on limited metadata with no full letter text available, this warning letter was issued to Samuel Zimmerman on September 5, 2018, regarding an "Other" product category. Without access to the subject line details or specific violation counts, the exact nature of the regulatory concerns cannot be determined from the available information. The issuing FDA office is also unknown, limiting clarity on the specific regulatory scope and product category involved. To understand the full nature of the violations and required corrective actions, the complete warning letter would need to be reviewed.